Literature DB >> 27601002

Key Molecular Drivers of Chronic Lymphocytic Leukemia.

Suliman A Alsagaby1, Paul Brennan2, Chris Pepper2.   

Abstract

Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLL; Molecular drivers; Pathogenicity; Prognosis; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27601002     DOI: 10.1016/j.clml.2016.08.008

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  3 in total

1.  In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Authors:  Suliman A Alsagaby; Danish Iqbal; Iqrar Ahmad; Harun Patel; Shabir Ahmad Mir; Yahya Awaji Madkhali; Atif Abdulwahab A Oyouni; Yousef M Hawsawi; Fahad A Alhumaydhi; Bader Alshehri; Wael Alturaiki; Bader Alanazi; Manzoor Ahmad Mir; Waleed Al Abdulmonem
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

2.  Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients.

Authors:  Ehsan Farzadfard; Tahereh Kalantari; Gholamhossein Tamaddon
Journal:  J Blood Med       Date:  2020-03-12

3.  Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia.

Authors:  Suliman A Alsagaby
Journal:  Oncol Rev       Date:  2019-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.